A recent study evaluated the efficacy of pembrolizumab across various cancers, classified according to tumor mutational load (TML) defined by whole-genome sequencing. Tumors exhibiting intermediate to high TML showed improved clinical benefit from pembrolizumab. This proof-of-concept study highlights clinical value of TML in patient selection, advancing precision immunotherapy and treatment strategies.

中文翻译：

---

肿瘤突变负荷：派姆单抗临床获益的新预测因子


最近的一项研究评估了派姆单抗对各种癌症的疗效，并根据全基因组测序定义的肿瘤突变负荷 (TML) 进行分类。表现出中等到高 TML 的肿瘤显示出派姆单抗改善的临床益处。这项概念验证研究强调了 TML 在患者选择、推进精准免疫治疗和治疗策略方面的临床价值。